Movement Alert｜WUXI BIO Rises 3.38% in Regular Trading, CXO Sector Momentum Sustained as Interim Results Approach

Market Focus

Aug 18

On August 18, WUXI BIO rose 3.38% in regular trading, trading at 47.64 HKD/share, with turnover of approximately 109 million HKD. The rise was driven by continued strength across the CXO sector and growing optimism ahead of the company's upcoming interim results review.

On the news front, peer Wuxi AppTec reported first-half revenue of 28.897 billion yuan, up 38.93% year-over-year, and raised its full-year guidance across all metrics, boosting sector-wide sentiment. WUXI BIO recently announced the sale of its 51.1% stake in Biogrunn to optimize capital allocation and sharpen its focus on core CRDMO operations. Additionally, the company's board is scheduled to review interim results on August 25, with the market holding positive expectations for earnings delivery.

Within the Life Sciences Tools and Services sector, GENSCRIPT BIO rose 7.82%, WUXI XDC gained 2.77%, and WUXI APPTEC advanced 0.39%, reflecting broad sector participation.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1142462789"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1142462789\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1142462789?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-18 09:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142462789","market":"us","top_or_hot":-1,"title":"Movement Alert｜WUXI BIO Rises 3.38% in Regular Trading, CXO Sector Momentum Sustained as Interim Results Approach","media":"Market Focus","content":"<p><p>On August 18, WUXI BIO rose 3.38% in regular trading, trading at 47.64 HKD/share, with turnover of approximately 109 million HKD. The rise was driven by continued strength across the CXO sector and growing optimism ahead of the company's upcoming interim results review.</p><p>On the news front, peer Wuxi AppTec reported first-half revenue of 28.897 billion yuan, up 38.93% year-over-year, and raised its full-year guidance across all metrics, boosting sector-wide sentiment. WUXI BIO recently announced the sale of its 51.1% stake in Biogrunn to optimize capital allocation and sharpen its focus on core CRDMO operations. Additionally, the company's board is scheduled to review interim results on August 25, with the market holding positive expectations for earnings delivery.</p><p>Within the Life Sciences Tools and Services sector, GENSCRIPT BIO rose 7.82%, WUXI XDC gained 2.77%, and WUXI APPTEC advanced 0.39%, reflecting broad sector participation.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WUXI BIO Rises 3.38% in Regular Trading, CXO Sector Momentum Sustained as Interim Results Approach</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WUXI BIO Rises 3.38% in Regular Trading, CXO Sector Momentum Sustained as Interim Results Approach\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-18 09:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 18, WUXI BIO rose 3.38% in regular trading, trading at 47.64 HKD/share, with turnover of approximately 109 million HKD. The rise was driven by continued strength across the CXO sector and growing optimism ahead of the company's upcoming interim results review.</p><p>On the news front, peer Wuxi AppTec reported first-half revenue of 28.897 billion yuan, up 38.93% year-over-year, and raised its full-year guidance across all metrics, boosting sector-wide sentiment. WUXI BIO recently announced the sale of its 51.1% stake in Biogrunn to optimize capital allocation and sharpen its focus on core CRDMO operations. Additionally, the company's board is scheduled to review interim results on August 25, with the market holding positive expectations for earnings delivery.</p><p>Within the Life Sciences Tools and Services sector, GENSCRIPT BIO rose 7.82%, WUXI XDC gained 2.77%, and WUXI APPTEC advanced 0.39%, reflecting broad sector participation.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"","article_id":"1142462789","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142462789","pubTimestamp":1787016825,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 18, WUXI BIO rose 3.38% in regular trading, trading at 47.64 HKD/share, with turnover of approximately 109 million HKD. The rise was driven by continued strength across the CXO sector and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02269":"药明生物"},"translate_title":"走势提醒|药明生物常规交易上涨3.38%，随着中期业绩临近，CXO板块势头持续","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1},"content_text":"On August 18, WUXI BIO rose 3.38% in regular trading, trading at 47.64 HKD/share, with turnover of approximately 109 million HKD. The rise was driven by continued strength across the CXO sector and growing optimism ahead of the company's upcoming interim results review.On the news front, peer Wuxi AppTec reported first-half revenue of 28.897 billion yuan, up 38.93% year-over-year, and raised its full-year guidance across all metrics, boosting sector-wide sentiment. WUXI BIO recently announced the sale of its 51.1% stake in Biogrunn to optimize capital allocation and sharpen its focus on core CRDMO operations. Additionally, the company's board is scheduled to review interim results on August 25, with the market holding positive expectations for earnings delivery.Within the Life Sciences Tools and Services sector, GENSCRIPT BIO rose 7.82%, WUXI XDC gained 2.77%, and WUXI APPTEC advanced 0.39%, reflecting broad sector participation.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}